Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

MedPlant · Harnessing the Molecules of Medicinal Plants

H2020Status: CLOSED1 July 201831 December 2023EU funding €2,499,999Call ERC-2017-ADG

Plants, as sessile organisms, synthesize complex molecules for defense and signaling. Humans have long exploited the potent medicinal activities of these plant natural products: artemisinin from sweet wormwood is used to cure malaria, vincristine from Madagascar periwinkle is used to treat cancer, and morphine from poppy alleviates pain. Synthetic biology approaches are being used with increasing success to overproduce these expensive molecules, which are often present at low levels in the plant. However, to pursue such approaches effectively, we must fully understand the biosynthetic pathways that generate these molecules. This pathway discovery process has been a major bottleneck in harnessing the chemical power of plants.Recent advances in sequencing, bioinformatics and metabolomics have provided the tools to address plant natural product metabolism on an unprecedented scale: we can now use inexpensive RNA-seq data, in combination with bioinformatic analyses and metabolomic data, for rapid identification of pathway-specific biosynthetic gene candidates. Here we use these advances, along with our expertise in chemistry, to unlock the extraordinary chemical diversity that is found within the ca. 3000 members of the plant-derived monoterpene indole alkaloid metabolites. By strategically selecting a group of molecules that are chemically diverse, yet biosynthetically and evolutionarily related, the gene discovery process will be dramatically accelerated (Objective 1). Moreover, using this strategy, we will uncover new biochemical mechanisms by which chemical diversity is generated in plants (Objective 2). Understanding these mechanisms will allow us to generate “unnatural” chemical diversity in the laboratory by creating production platforms that produce new-to-nature molecules that may potentially have important applications (Objective 3).

Consortium · 2 organisations

coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

DE · €2,399,999

participant

JOHN INNES CENTRE

UK · €100,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.